Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers December 12, 2017
Pharmacy Choice - News - Over-the-Counter Drugs - December 12, 2017

Pharmacy News

 Over-the-Counter Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 36     Next >>     Go To Page:

12/12/17 - AbbVie Announces Phase 3 Study of VENCLEXTA?/ VENCLYXTO? (venetoclax) in Combination with Rituxan (rituximab) Meets its Primary Endpoint
AbbVie, a research and development based global biopharmaceutical company, today announced the first presentation of efficacy and safety results from MURANO, an international, multicenter, open-label, randomized Phase 3 study of VENCLEXTA?/ VENCLYXTO? in combination with Rituxan compared with bendamustine in combination with Rituxan in pat
12/12/17 - BioElectronics Announces ActiPatch: Over-The-Counter Alternative to Opioids
BioElectronics Corporation, the maker of advanced wearable consumer pain management medical device, ActiPatch, announced today the launch of ActiPatch for Over-The-Counter, drug-free pain relief as an alternative to Opioids. ActiPatch is approved by the FDA for Over-The-Counter sales for the adjunctive treatment of pain due to: 1) Osteoarthritis
12/12/17 - BioMarin Provides 1.5 years of Clinical Data for Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A
SAN RAFAEL- BioMarin Pharmaceutical Inc. announced today an update to its previously reported results of an open-label Phase 1/ 2 study of valoctocogene roxaparvovec, an investigational gene therapy treatment for severe hemophilia A. The updated results will be presented during an oral presentation at the 59th American Society of Hematology Annual.
12/12/17 - BioPharmX Reports Third Quarter 2018 Financial Results
MENLO PARK, Calif.- BioPharmX Corporation, a specialty pharmaceutical company focusing on dermatology, today announces its financial results for the third quarter ended October 31, 2017. 'We achieved important regulatory and financial milestones during the quarter,' said BioPharmX president Anja Krammer.' The Food and Drug Administration concurred
12/12/17 - New generic Viagra is here, cutting pharmacy bills for Michigan men in search of erections [Detroit Free Press]
Pfizer, the maker of Viagra, on Monday introduced the first official generic version of its blockbuster impotence pill. Some of the lowest consumer prices for generic Viagra are already offered by specialized pharmacies as well as new e-commerce startups, such as New York- based Roman Health, which has an online prescription service and mail-order
12/12/17 - Orexo Discloses More Information About the Improved Market Access Position for Zubsolv US in 2018
Orexo AB today announces specific information about the improved market access position for Zubsolv sublingual tablet in the US effective January 1, 2018, and previously announced in the Interim Report for the third quarter of 2017. Recently, the Formulary List of Covered Drugs for 2018 has been announced by all managed care programs, thus enabling
12/12/17 - Pharma and Healthcare Social Media Marketing Market Will Make a Huge Impact in Near Future: Pharma and Healthcare Social Media Marketing: Global Industry Analysis and Opportunity Assessment 2015 2025
Valley Cottage, NY 12/11/2017 Social media platforms refer to the interaction among the people that involves creation, sharing and exchange of information and ideas in virtual networks and communities. For instance, in second week of January 2014, the U.S. Food and Drug Administration released a guidance draft for industry that needs to fulfi
12/12/17 - Specialty pharmacy scrutiny hits again with state`s focus on Horizon meds [Tehran Times (Iran)]
In its 2015 and 2016 formularies, top pharmacy benefits manager Express Scripts excluded the pills, saying they were pricey substitutes for readily available, off-patent products. Horizon, however, says its single-pill formulations aren`t just more convenient for patients to take, but that the drugs` official FDA labels say the two brands have no r
12/12/17 - The Therapeutic Potential of Pharmacologically Active Cannabinoids
But InMed Pharmaceuticals, Inc. has initiated a scientific paradigm shift in discovering potential breakthrough cannabinoid-based therapies that advances far beyond basic cannabinoid production and the over-the-counter sales of oils and elixirs. The company s proprietary biosynthesis process sets it apart from the operations of companies like...
12/11/17 - BioMarin Highlights New Results for Gene Therapy Valoctocogene Roxaparvovec at the 2017 American Society of Hemophilia (ASH) Meeting
BioMarin Pharmaceutical Inc. announced updates on valoctocogene roxaparvovec, an investigational gene therapy treatment for severe hemophilia at ASH. Please see full release issued December 9, 2017 here for details. "The confluence of new medicines and advanced treatment approaches for hemophilia has created an unprecedented opportunity to impro
12/11/17 - Janssen Submits Supplemental New Drug Application to FDA Seeking New Indications for XARELTO (rivaroxaban) for Patients with Chronic Coronary and/or Peripheral Artery Disease (CAD/PAD)
Janssen Research& Development, LLC today announced it has submitted a supplemental New Drug Application to the U.S. Food and Drug Administration for two new XARELTO vascular indications: reducing the risk of major cardiovascular events such as CV death, heart attack or stroke in patients with chronic coronary and/or peripheral artery disease,
12/11/17 - Multiple taxation, duties killing Nigerian manufacturers Nebe, Pharmatex MD [Sun, The (Nigeria)]
By Isaac Anumihe and Doris Obinna. Managing Director of Pharmatex Industries, Prince Christopher Obiora Nebe, was the sole representative of a multinational pharmaceutical company in Nigeria Hovid Industries before he ventured into drug manufacturing business, five years ago. Nebe listed some of the challenges of Nigeria s manufacturing se
12/11/17 - Phase III IMmotion151 Study Showed Genentech's TECENTRIQ (Atezolizumab) and Avastin (Bevacizumab) Reduced the Risk of Disease Worsening or Death for the Initial Treatment of Certain People with Advanced Kidney Cancer
Genentech, a member of the Roche Group, today announced that the Phase III IMmotion151 study met its co-primary endpoint of investigator-assessed progression-free survival and demonstrated that the combination of TECENTRIQ and Avastin provided a statistically significant and clinically meaningful reduction in the risk of disease worsening or.
12/11/17 - Primary Analysis Results From Novartis Pivotal JULIET Trial Show Kymriah(TM) (Tisagenlecleucel) Sustained Complete Responses at Six Months in Adults With R/r DLBCL, a Difficult-to-Treat Cancer
The data from this pivotal trial, led by researchers from the University of Pennsylvania, show an overall response rate of 53 percent, with 40 percent achieving a complete response and 14 percent achieving a partial response among 81 infused patients with three or more months of follow-up or earlier discontinuation. Results from this study of Kymri
12/11/17 - Radient Technologies Inc. Announces Master Services Agreement with Terra Life Sciences
Radient Technologies Inc. announces the signing of a Master Services Agreement to produce cannabis extracts for the Terra Life Sciences group, a private, Alberta- based pharmaceutical manufacturer whose ACMPR license is expected in the near future. With its subsidiary Olds SoftGels Inc and OSG's production capacity of over 2.5 billion softgel capsu
12/10/17 - GNW-News: Primary analysis results from Novartis pivotal JULIET trial show Kymriah(TM) (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer (english)
Novartis International AG/ Primary analysis results from Novartis pivotal JULIET trial show Kymriah (TM) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer. Basel, December 10, 2017- Novartis today announced updated results from the JULIET clinical trial demonstrating sustained responses with Kymriah (T
12/10/17 - Primary analysis results from Novartis pivotal JULIET trial show Kymriah(TM) (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer
Novartis International AG/ Primary analysis results from Novartis pivotal JULIET trial show Kymriah (TM) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer. The data from this pivotal trial, led by researchers from the University of Pennsylvania, show an overall response rate of 53% (95% confidence inte
12/10/17 - Primary analysis results from Novartis pivotal JULIET trial show Kymriah? (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer
Novartis today announced updated results from the JULIET clinical trial demonstrating sustained responses with Kymriah? suspension for intravenous infusion, formerly CTL019, in adult patients with relapsed or refractory diffuse large B-cell lymphoma. The data from this pivotal trial, led by researchers from the University of Pennsylvania, show
12/9/17 - BioMarin Provides 1.5 years of Clinical Data for Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A at 59th American Society of Hematology (ASH) Annual Meeting Concurrent with NEJM Publication
BioMarin Pharmaceutical Inc. announced today an update to its previously reported results of an open-label Phase 1/ 2 study of valoctocogene roxaparvovec, an investigational gene therapy treatment for severe hemophilia A. The updated results will be presented during an oral presentation at the 59th American Society of Hematology Annual Meeting an
12/9/17 - Generic Viagra to hit the market [The Pittsburgh Tribune-Review]
Drugmaker Pfizer Inc. will begin selling the generic version, in white pill form, for about $32 a pill, half of Viagra's price. Pfizer negotiated a deal four years ago allowing Teva Pharmaceuticals USA Inc. to begin selling a generic version in the United States on Monday, Forbes reported. Therefore, Pfizer plans to release its own white pill at ha
12/8/17 - Bharat Book Bureau: Current and Future Trends in Rx-to-OTC Switching with Insight from Key Industry Opinion Leaders
Rx-to-OTC switching is the process in which a drug which has formerly been marketed as a prescription-only Rx drug is authorized for sale to the general public, without the need for a prescription. For patients and healthcare providers, OTC products can reduce the cost of medical treatment and allow easier access of drugs to patients, and for pharm
12/8/17 - CHPA Submits Comments to FDA Regarding the Development of a Pre-DSHEA Ingredients List
'CHPA members are committed to maintaining the highest levels of quality in the manufacture and marketing of dietary supplements,' said CHPA president and CEO Scott Melville.' We applaud FDA for their thoughtful, inclusive approach to the development and implementation of a process that will ensure continued consumer access to safe and beneficial d
12/8/17 - Over The Counter (OTC) Drugs Market 2017 Global Trend, Segmentation and Opportunities Forecast To 2022
Over The Counter Drugs- Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2022. This report studies Over The Counter Drugs in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and fore
12/7/17 - Bharat Book Bureau: Global Canine Oral Chewable Tablets Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to 2023
Global Canine Oral Chewable Tablets Market. Canine Oral Chewable Tablets Market are the oral dosage form of medication with additives used to treat various types of canine diseases such as arthritis, canine congestive heart failure, tick and fleas infections, and among others. However, stringent regulatory policies for the approval of veterinary...
12/7/17 - BioPharmX Reports Third Quarter 2018 Financial Results
BioPharmX Corporation, a specialty pharmaceutical company focusing on dermatology, today announces its financial results for the third quarter ended October 31, 2017.. "We achieved important regulatory and financial milestones during the quarter," said BioPharmX president Anja Krammer. "The Food and Drug Administration concurred with the phase
Articles(s): 1 - 25 of 36     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415